News

Ideas That Generate Results

The global double barreled antibodies market is experiencing a remarkable growth due to increasing cancer epidemics globally resulting in increasing demand for bi-specific or double barreled antibodies. Cancer constitutes a key challenge to development, deflating social and economic advancements throughout the world. According to American cancer Society, Non-Hodgkin lymphoma (NHL) is one of the most common cancers in the United States, accounting for about 4% of all cancers. Similarly, the GLOBOCAN estimates of Non-Hodgkin Lymphoma in Europe for 2020 is around 54,074 males and 47,259 females. In such a scenario, double barreled antibodies have emerged as one of the chief revenue generator for the pharmaceutical companies working individually or in collaboration with cancer research institutes for development of double barreled antibodies. These include Amgen, Roche, Regeneron, Aptevo, AbbVie, Glenmark, OncoMed Pharma, Ligand Pharma, amongst others. The Double Barreled Antibodies market globally is expected to become much more organized and consolidated with the technological advancements and debut makers that are entering into this industry.
 
According to a new research report by RNCOS entitled, “Global Double Barreled Antibodies Drug Sales (BLINCYTO & Removab), Pipeline Analysis (By Phase, Technology, and Indication), & Global Market Forecasts 2022”, market is expected to grow at a CAGR of around 29.8% during 2016-2022. Rising cancer epidemics, increasing demand for bi-specific antibodies, T-cell bi-specific antibody mediated immunotherapies are some of the major factors which will administer the growth of this industry.
 
Research Analysis and Highlights
The report is dispersed across 80 pages and provides an in-depth research and rational analysis of the current status and future prospects of the Global Double Barreled Antibody Industry. The report also provides a clear picture of the current status of double barreled antibodies in pipeline followed by emerging trends and developments. Additionally, the study includes all double barreled antibodies represented that are under various clinical phases of development. The report further highlights segmentation of the double barreled antibody pipeline based on clinical phase, cancer indication, and technology, as well as the individual share of each segment. At the end, with special focus on key players in Double Barreled Antibody industry, the research provides valuable information to the investors and debut makers who are looking forward to enter in this market.
 
Some of the salient features of the report include:
 
•        T-cell Bi-specific antibody mediated immunotherapy
•        Rising demand for bi-specific antibodies
•        Double Barreled Antibody Market forecasts to 2022
•        Current analysis of potential Double Barreled Antibodies in pipeline
 
For FREE SAMPLE of this report visit: http://www.rncos.com/Report/IM907.htm
 
Check Related REPORTS on: http://www.rncos.com/Healthcare_Industry.htm